Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 20;23(4):377-391.
doi: 10.1080/26895269.2022.2025551. eCollection 2022.

Thrombophilia and hormonal therapy in transgender persons: A literature review and case series

Marianne Kerrebrouck  1 , Anna Vantilborgh  2 , Sarah Collet  1 , Guy T'Sjoen  1
Affiliations

Thrombophilia and hormonal therapy in transgender persons: A literature review and case series

Marianne Kerrebrouck et al. Int J Transgend Health. .

Abstract

Background: Venous thromboembolism (VTE) is a rare side effect of hormonal therapy in transgender persons. Prothrombotic genetic variants can increase this risk. For this reason, previous VTE and/or genetic thrombophilia may be considered by some as contraindications to hormonal treatment. Aim: To formulate directions for clinical practice about the indications for thrombophilia screening and when to consider combination therapy of therapeutic anticoagulation and hormonal treatment as a safe alternative to withholding hormonal treatment. Methods: We conducted a literature search and describe a case series. All adult patients with gender dysphoria and a known prothrombotic genetic variant or history of VTE were invited by letter to participate in this study. Results: In our center, thrombophilia screening before start of hormonal treatment was restricted to those with a personal or family history of VTE. Sixteen individuals with a history of VTE and/or an underlying prothrombogenic condition were described. The time of follow up varied from 4 months to 20 years. Seven trans women had a positive thrombophilia screening (2 Factor V Leiden (FVL), 1 FVL + anticardiolipin antibodies, 1 FVL + high Factor VIII coagulant activity, 1 protein C deficiency, 1 prothrombin mutation, 1 positive lupus anticoagulant). Three trans women experienced an unprovoked VTE after start of hormonal therapy of which one lead to a positive thrombophilia screening. One VTE event in a trans woman was assumed to be provoked by surgery. Five trans men were identified with a prothrombogenic mutation (3 FVL, 1 protein C deficiency, 1 prothrombin mutation). One trans man, with a negative thrombophilia screen, experienced multiple provoked VTE events before start of hormonal therapy. Conclusion: Based on our literature review and case series we offer guidance when confronted with patients with previous VTE and/or genetic thrombophilia requesting hormonal interventions.

Keywords: Anticoagulation; guidance; hormonal therapy; thrombophilia; thrombosis; transgender; case series.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Agledahl, I., Brodin, E., Svartberg, J., & Hansen, J. B. (2009). Impact of long-term testosterone treatment on plasma levels of free TFPI and TF-induced thrombin generation ex vivo in elderly men with low testosterone levels. Thrombosis and Haemostasis, 102(11), 945–950. 10.1160/TH09-02-0090 - DOI - PubMed
    1. Anderson, F. A., Jr., Wheeler, H. B., Goldberg, R. J., Hosmer, D. W., Patwardhan, N. A., Jovanovic, B., Forcier, A., & Dalen, J. E. (1991). A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Archives of Internal Medicine, 151(5), 933–938. https://www.ncbi.nlm.nih.gov/pubmed/2025141 10.1001/archinte.151.5.933 - DOI - PubMed
    1. Anderson, R. A., Ludlam, C. A., & Wu, F. C. (1995). Haemostatic effects of supraphysiological levels of testosterone in normal men. Thrombosis and Haemostasis, 74(2), 693–697. https://www.ncbi.nlm.nih.gov/pubmed/8585008 10.1055/s-0038-1649799 - DOI - PubMed
    1. Asscheman, H., Giltay, E. J., Megens, J. A., de Ronde, W. P., van Trotsenburg, M. A., & Gooren, L. J. (2011). A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. European Journal of Endocrinology, 164(4), 635–642. 10.1530/EJE-10-1038 - DOI - PubMed
    1. Asscheman, H., Gooren, L. J., & Eklund, P. L. (1989). Mortality and morbidity in transsexual patients with cross-gender hormone treatment. Metabolism, 38(9), 869–873. 10.1016/0026-0495(89)90233-3 - DOI - PubMed

LinkOut - more resources